Outward foreign direct investment from India reached $4.34 billion in September, which is a 14% increase from last year. However, this figu...

The company outperformed the market by 1.1 times in both chronic and acute therapies. Cardiac and anti-diabetes brands registered growth of...

Tata Consumer Products reported a 16% year-on-year profit increase to Rs 470 crore in Q2 FY27, with revenue rising 14% to Rs 5,661 crore. S...

Coforge shares fell despite strong Q2 results and brokerages raising target prices. Net profit surged 56.5% year-on-year to Rs 588.1 crore,...

Indian equity markets have faced a decline for four consecutive sessions, with the Nifty falling significantly. Various factors, including ...

The review comes against the backdrop of the Uniform Code for Pharmaceutical Marketing Practices (UCPMP), which was introduced in 2015 as a...

Infosys Q2 Results: IT services major Infosys Ltd on Friday reported 6% year-on-year (YoY) growth in its consolidated net profit at Rs 7,82...

Dr Reddy’s Laboratories has expanded its generic semaglutide portfolio with Obeda Pro and Obeda Plus after supplies of its original Obeda i...

Uniqlo India's revenue increased by 44% to Rs 1,724 crore in the last financial year. The brand's focus on everyday essentials contrasts wi...

The company’s food delivery gross order value (GOV) increased 17.7% year-on-year to Rs 10,054 crore, up 5.9% from the previous month. Swigg...

India Post has reported a revenue growth of 25% year-on-year for the September quarter. The increase was largely driven by a 71% rise in pa...

The International Gemological Institute recently announced an impressive 43.14 percent growth in profit after tax for the previous quarter....

Sun Pharmaceutical Industries plans to raise ₹10,000 crore through two tranches of rupee-denominated bonds. The funds will help refinance b...

India's pharmaceutical companies are expected to have a mixed performance in the upcoming September quarter. Companies like Sun Pharmaceuti...

Ixigo has reported a remarkable turnaround for the September quarter, showcasing a 13% year-on-year revenue growth, reaching Rs 321 crore. ...

From a technical perspective, the 23,000–23,100 zone remains an immediate resistance level for the Nifty, according to Ponmudi R, CEO of En...

At CPHI Milan, Indian pharma players are looking beyond traditional exports, using partnerships, licensing, CDMO, and differentiated produc...